DoD Kidney Cancer, Academy of Kidney Cancer Investigators – Leadership Award
ID: 355138Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355138
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Kidney Cancer Academy of Kidney Cancer Investigators – Leadership Award, aimed at fostering innovative kidney cancer research and leadership development among early-career investigators. This funding opportunity seeks applications for an Academy Director and Deputy Director to lead the Academy, with a focus on enhancing research capacity, collaboration, and mentorship in kidney cancer studies. The initiative is critical for advancing understanding of kidney cancer biology and therapeutic strategies, ultimately improving patient care. The total estimated funding for this program is $2.4 million, with individual awards capped at $1.5 million for a performance period of up to five years. Key deadlines include a pre-application submission by August 29, 2024, and a full application due by September 19, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524KCRPAKCILA_GG_Final.pdf
    The Department of Defense (DOD) is announcing the FY24 Kidney Cancer Academy of Kidney Cancer Investigators – Leadership Award under the Defense Health Program. This funding opportunity aims to support innovative kidney cancer research with a focus on leadership development for early-career investigators. Total appropriations for this program since its inception in 2017 amount to $235 million, with an allocation of $50 million for FY24. Applications must contribute to understanding kidney cancer biology, therapeutic strategies, and improving patient care. Key dates include a pre-application deadline of August 29, 2024, and a full application deadline on September 19, 2024. Eligible applicants include independent kidney cancer researchers with an established record in mentorship. Each proposal must specify a minimum of three pilot projects conducted collaboratively among Academy leaders and scholars. Primary funding will not support clinical trials but encourages collaborations across military and civilian sectors to advance kidney cancer research effectively. The anticipated budget for this award is capped at $1,500,000 for a maximum performance period of five years. This initiative underlines the commitment to fostering a new generation of kidney cancer researchers to significantly impact the field.
    Similar Opportunities
    DOD Glioblastoma, Transformative Consortium Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Glioblastoma Transformative Consortium Award, aimed at advancing research to improve outcomes for glioblastoma patients. This grant seeks proposals for innovative, multidisciplinary projects that collectively address a central hypothesis, requiring collaboration among at least four distinct projects and the inclusion of a consumer advocate. With an estimated total program funding of $9 million, the application process includes a pre-application deadline of December 23, 2024, and a full application deadline of January 13, 2025. Interested applicants can reach the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507 for further assistance.
    Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Institutional Network Award (U2C) to enhance training in kidney, urologic, and hematologic research. This funding opportunity aims to foster a collaborative environment by inviting institutions to submit a unified application that supports a cohort of trainees and early-career investigators, with a strong emphasis on partnerships among institutions within metropolitan areas. The initiative is crucial for reshaping research training and promoting scientific collaboration, ensuring that the next generation of researchers is equipped to address complex biomedical challenges. Applications will be accepted starting October 16, 2023, with a submission deadline of September 27, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Approaches for Reducing Disparities in Kidney Health
    Active
    Office of the Assistant Secretary for Health
    The Office of the Assistant Secretary for Health is forecasting a federal grant opportunity titled "Innovative Approaches for Reducing Disparities in Kidney Health" aimed at addressing chronic kidney disease (CKD) disparities through community-based strategies. This grant will support demonstration projects that adapt evidence-based approaches to reduce CKD and its related risk factors, particularly focusing on groups disproportionately affected by these health issues. With an estimated total program funding of $2 million, the agency anticipates awarding four grants, each ranging from $425,000 to $500,000, with applications due by February 11, 2025. Interested applicants can reach out to Alana Sutherland at OMHGrants@hhs.gov or by phone at 301-945-3668 for further information.
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    NCI Continuing Umbrella of Research Experiences (CURE) Mentored Clinical Scientist Research Career Development Award (K08 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCI Continuing Umbrella of Research Experiences (CURE) Mentored Clinical Scientist Research Career Development Award (K08), aimed at fostering diversity within the cancer research workforce. This grant supports clinical scientists with doctoral degrees who are underrepresented in health-related research, providing salary support for a 3-5 year period to gain intensive research training in various cancer research fields, particularly focusing on health disparities. The program is designed to enhance the research capabilities of awardees, preparing them for independent research careers in basic biomedical, behavioral, or translational cancer research. Interested applicants should note that the application period opens on January 12, 2025, with a submission deadline of February 12, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-320.html.
    Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)." This initiative aims to support the development of innovative tools and technologies that address significant challenges in kidney, urologic, and hematologic research, encouraging high-risk, exploratory projects that differ from traditional R01 grants. The funding, with a maximum budget of $275,000 over two years, is open to a diverse range of eligible applicants, including various educational institutions and community organizations, with applications due by January 7, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-119.html.
    NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22), aimed at supporting senior postdoctoral fellows in their transition to independent research roles. This grant specifically targets candidates from diverse backgrounds, with the objective of fostering an inclusive research workforce and enhancing cancer research capabilities. The K22 award provides three years of salary and research funding, encouraging the development of independent research projects, particularly those leading to clinical trials. Interested applicants must adhere to NIH guidelines and submit their applications by January 7, 2028, with further details available at NIH Grants. For inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Paul Calabresi Career Development Award for Clinical Oncology (K12), aimed at supporting institutional research career development programs for clinical scientists in cancer research. This initiative emphasizes training for clinical scientists who aspire to lead independent clinical trials or contribute to existing trials, thereby enhancing the field of clinical cancer research. The NOFO is anticipated to be released in November 2024, with the first application deadline set for February 2025, and the estimated award date is January 5, 2026. Interested applicants are encouraged to begin developing collaborations and applications in advance, as there are no cost-sharing requirements associated with this grant opportunity.
    Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Kidney Technology Development Research Education Program (R25), aimed at fostering educational initiatives that encourage diverse individuals to pursue careers in nephrology and kidney technology development. This program seeks applications from institutions proposing innovative educational activities, including hands-on research projects, multidisciplinary teamwork, and training in entrepreneurship and regulatory processes, with a focus on recruiting undergraduate, graduate, and medical students from engineering and quantitative backgrounds. With a total funding allocation of $300,000 for FY 2025 and FY 2026, applications are due by June 15, 2025, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the program's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-009.html.
    Limited Competition: AIDS Malignancy Consortium (AMC; UM1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Limited Competition Notice of Funding Opportunity (NOFO) for the AIDS Malignancy Consortium (AMC), aimed at enhancing research and clinical interventions for HIV-associated malignancies. This initiative seeks to establish a comprehensive infrastructure that includes a Coordination Center, Clinical Trial Sites, Network Laboratories, and a Statistical Center, focusing on areas such as Kaposi Sarcoma, hematologic malignancies, and HPV-associated cancers. With a funding commitment of $18.1 million for fiscal year 2025 and a total budget cap of $97 million over five years, eligible applicants, primarily small businesses, must adhere to NIH guidelines and submit their applications by January 10, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-028.html.